Liposomal particles, methods of making same and uses thereof
Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
1. A plurality of liposomal particles, each liposomal particle having a substantially spherical geometry and comprising:
a lipid bilayer comprising a plurality of lipid groups, and
about 10-40 oligonucleotides on the external side of the lipid bilayer, wherein each oligonucleotide is a toll-like receptor 9 (TLR9) agonist, wherein each oligonucleotide is an oligonucleotide-lipid conjugate containing one lipophilic tethered group, wherein each lipophilic tethered group is adsorbed into the external side of the lipid bilayer, wherein said plurality of liposomal particles has a mean diameter of less than or equal to about 40 nanometers (nm) and wherein all oligonucleotides are single-stranded.
2. The plurality of liposomal particles of claim 1 , wherein the plurality of lipid groups comprises a lipid selected from the group consisting of the phosphatidylcholine, phosphatidylglycerol, and phosphatidylethanolamine family of lipids.
3. The plurality of liposomal particles of claim 2 , wherein said lipid is selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn-phosphatidylcholine (DMPC), 1-palmitoyl-2-oleoyl-sn-phosphatidylcholine (POPC), 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DSPG), 1,2-dioleoyl-sn-glycero-3-phospho-1′-rac-glycerol) (DOPG), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), and 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (DPPE).
4. The plurality of liposomal particles of claim 1 , wherein the lipophilic tethered group is tocopherol or cholesterol.
5. The plurality of liposomal particles of claim 1 , wherein each oligonucleotide contains a modified backbone.
6. The plurality of liposomal particles of claim 1 , wherein the TLR9 agonist is a CpG-containing oligonucleotide.
7. The plurality of liposomal particles of claim 6 , wherein the CpG-containing oligonucleotide has the following sequence: 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO: 8).
8. The plurality of liposomal particles of claim 1 , wherein each oligonucleotide is a modified oligonucleotide having phosphorothioate linkages.
9. The plurality of liposomal particles of claim 1 , wherein said plurality of liposomal particles has a mean diameter of less than or equal to 35 nanometers (nm).
10. The plurality of liposomal particles of claim 9 , wherein said plurality of liposomal particles has a mean diameter of less than or equal to 30 nanometers (nm).
11. The plurality of liposomal particles of claim 1 , wherein the lipophilic tethered group is at the 3′-end of each oligonucleotide.
12. A method for treating cancer, comprising administering to a patient a plurality of liposomal particles, each liposomal particle having a substantially spherical geometry and a lipid bilayer comprising a plurality of lipid groups, and about 10-40 oligonucleotides on the external side of the lipid bilayer, wherein all oligonucleotides are single-stranded, wherein each oligonucleotide is a toll-like receptor 9 (TLR9) agonist, wherein each oligonucleotide is an oligonucleotide-lipid conjugate containing one lipophilic tethered group, wherein each lipophilic tethered group is adsorbed into the lipid bilayer, wherein said plurality of liposomal particles has a mean diameter of less than or equal to about 40 nanometers (nm), and wherein the administering treats the cancer.
13. The method of claim 12 , wherein the lipophilic tethered group is tocopherol or cholesterol.
14. The method of claim 12 , wherein each oligonucleotide contains a modified backbone.
15. The method of claim 12 , wherein the TLR9 agonist is a CpG-containing oligonucleotide.
16. The method of claim 15 , wherein the CpG-containing oligonucleotide has the following sequence: 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO: 8).
17. The method of claim 12 , wherein each oligonucleotide is a modified oligonucleotide having phosphorothioate linkages.
18. The method of claim 12 , wherein said plurality of liposomal particles has a mean diameter of less than or equal to 35 nanometers (nm).
19. The method of claim 18 , wherein said plurality of liposomal particles has a mean diameter of less than or equal to 30 nanometers (nm).
20. The method of claim 12 , wherein the lipophilic tethered group is at the 3′-end of each oligonucleotide.